Condylomata Acuminata, Papillomavirus Infections, Sexually Transmitted Diseases
Conditions
Brief summary
Ranpirnase in topical formulation is an antiviral drug being evaluated for the topical treatment of anogenital warts. The aims of this study is to evaluate the efficacy and safety of a topical formulation of ranpirnase in subjects with genital warts.
Detailed description
The study consists of the evaluation of 4 weeks exposure to the study product; designed as randomized, double blinded, against vehicle to study the effects of 1 mg/ml concentration of ranpirnase on anogenital warts. The dermal reaction are scored on a scale that describes the amount of erythema, edema, and other features indicative of irritation. The clinical response are be scored on the basis of the percentage of the reduction of the lesions in size and number.
Interventions
DRUGRanpirnase
Topical application by subject
DRUGVehicle
Vehicle control
Sponsors
Tamir Biotechnology, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* Diagnosis of external genital / perianal warts with at least 2 warts and no more than 30 lesions * Accept to follow study instructions / signature of IC * Abstain from sexual intercourse for 6 hours after applying the study product during the time of the study.
Exclusion criteria
* Any topical and/or destructive treatments for external genital warts within 4 weeks (within 12 months for imiquimod and within 12 weeks for sinecatechins) prior to enrollment (i.e., the randomization visit) * Non pregnant. For women in reproductive age it would be required pregnancy test, and the use of double barrier contraceptives. * Any of the following conditions: * Known allergy to the study product * Internal (rectal, urethral) warts that required or were undergoing treatment; * A dermatological disease (e.g., psoriasis) or skin condition in the area, which may interfere with the evaluation. * Imiquimod 5% cream (Aldara®) * Any marketed or investigational HPV vaccines * Sinecatechins (Veregen) * Interferon or interferon inducers * Cytotoxic drugs * Immunomodulators or immunosuppressives * Oral or parenteral corticosteroids (inhaled/intranasal steroids are permitted) * Oral antiviral drugs (with the exception of HAART, oral acyclovir and acyclovir related drugs) for suppressive or acute therapy herpes; or oseltamivir for prophylaxis or for influenza) * Topical antiviral drugs (including topical acyclovir and acyclovir related drugs) in the areas under treatment * Podophyllotoxin/Podofilox in the treatment areas * Any topical prescription medications in the treatment areas * Dermatologic procedures or surgery in the treatment areas
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Size of lesions | Up to 60 days | The primary endpoint is the percentage change from baseline in total area of lesions at Week 8 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of lesions | Up to 60 days | Number of lesions present at Week 8 |
Countries
Bolivia
Outcome results
None listed